SCHEMBL23461920

SCHEMBL23461920

CC1(C(NC(=O)c2ccc3ccccc3c2OCc2ccc(C(F)(F)F)cc2)C(=O)O)CCCCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 5/20 0.59
▸ DRD4 P21917 1/20 0.38
▸ P2RX1 P51575 1/20 0.37
▸ P2RX3 P56373 1/20 0.37
▸ P2RX4 Q99571 1/20 0.37
▸ P2RX7 Q99572 1/20 0.37
▸ KIFC1 Q9BW19 1/20 0.37
▸ MME P08473 1/20 0.37
▸ ACE P12821 1/20 0.37
▸ CPA1 P15085 1/20 0.37
▸ ACE2 Q9BYF1 1/20 0.37
▸ SLC6A5 Q9Y345 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ PPARD Q03181 1/20 0.36
▸ TRPV1 Q8NER1 1/20 0.36
▸ TACR1 P25103 1/20 0.36
▸ SENP5 Q96HI0 1/20 0.36
▸ SENP2 Q9HC62 1/20 0.36
▸ SENP1 Q9P0U3 1/20 0.36
▸ MCHR1 Q99705 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23461082 0.96 CXCR2 (0.60) CXCR2DRD4P2RX1P2RX3P2RX4
SCHEMBL23460893 0.91 CXCR2 (0.49) CXCR2KIFC1MMEACECPA1
SCHEMBL23460895 0.91 CXCR2 (0.49) CXCR2KIFC1MMEACECPA1
SCHEMBL23461203 0.91 CXCR2 (0.58) CXCR2DRD4KIFC1MMEACE
SCHEMBL23460978 0.90 CXCR2 (0.47) CXCR2PPARGTRPV1
SCHEMBL23461506 0.90 CXCR2 (0.49) CXCR2KIFC1MMEACECPA1
SCHEMBL23461509 0.90 CXCR2 (0.49) CXCR2KIFC1MMEACECPA1
SCHEMBL23460874 0.89 CXCR2 (0.46) CXCR2KIFC1MMEACECPA1
SCHEMBL23460875 0.89 CXCR2 (0.46) CXCR2KIFC1MMEACECPA1
SCHEMBL38146973 0.89 CXCR2 (0.46) CXCR2KIFC1MMEACECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885DRD4 4290/4885P2RX1 766/4885
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885DRD4 2554/4885P2RX1 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback